Breast cancer triple negative
Drug research and approvals for breast cancer triple negative: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 353 studies of breast cancer triple negative are recruiting on ClinicalTrials.gov, and Health Canada has authorized 31 drug trials for it since 2013.
- Recruiting worldwide: 353
- Trials authorized in Canada: 31
- FDA orphan approvals: 0
- EU medicines: 0
- Pucotenlimab and Anlotinib in Combination With ChemotherapyNCT07896668 · Phase 2 · Zhejiang Cancer Hospital · starts Sep 1, 2025
- Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative…NCT07880600 · Not reported · Fujian Cancer Hospital · starts Oct 8, 2026
- A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or…NCT07876557 · Phase 2 · Shanghai Junshi Bioscience Co., Ltd. · starts Oct 22, 2026
- Clinical and Therapeutic Outcomes by Molecular Subtype in Breast CancerNCT07856225 · Not reported · Fundación Santa Fe de Bogota · starts Dec 1, 2025
- Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for…NCT07844473 · Not applicable · King Faisal Specialist Hospital & Research Center · starts Jul 24, 2026
- Role of Tumor Microbiota in the Response to Neoadjuvant Therapy in Patients Affected by Triple Negative Breast CancerNCT07808086 · Not reported · Istituti Clinici Scientifici Maugeri SpA · starts Sep 1, 2026
- A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid TumorsNCT07801508 · Phase 1 · Novartis Pharmaceuticals · starts Sep 8, 2026
- Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve…NCT07776951 · Not applicable · University of Milan · starts Feb 1, 2026
- Establishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC StudyNCT07773818 · Not reported · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · starts Aug 6, 2026
How its trials ended
920 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 216 whose ending is known, 24% met their primary endpoint, 7% missed it and 69% stopped early.
- Ongoing44949%
- Completed, result not reported15617%
- Status unknown9911%
- Stopped: other or unclear738%
- Met its primary endpoint526%
- Stopped: sponsor or business decision354%
- Stopped: enrollment or feasibility192%
- Stopped: lack of efficacy162%
- Missed its primary endpoint152%
- Stopped: funding51%
- Stopped: safety1<1%
| Jul 27, 2026 | Shorter anthracycline-free chemo immunotherapy adapted to pathological response in early triple negative breast cancer (SCARLET), a randomized phase III studyCarboplatin / Pembrolizumab (keytruda) | BC Cancer, Part of The Provincial Health Services Authority | Pending |
| Dec 17, 2025 | Rebooting sensitivity to checkpoint blockade therapy in triple-negative breast cancer with isunakinra (resett- i)Isunakinra | University Health Network | Ongoing |
| Nov 13, 2025 | Fmt in triple negative breast cancer guided by ctdna (FRIDA)Fecal transplantation / Fecal microbial therapy | Dr. Mark Basik | Pending |
| Oct 15, 2025 | A phase II study of first-line sacituzumab govitecan in advanced untreated triple negative breast cancer patientTrodelvy (sacituzumab govitecan) | BC Cancer | Ongoing |
| Jul 10, 2025 | Determine whether administering celecoxib during radiotherapy can reduce the risk of recurrence of triple-negative breast cancer. pilot studyCelecoxib | Ciusss De L'Estrie - Centre Hospitalier Universitaire De Sherbrooke | Pending |
| Mar 19, 2025 | A phase 2, umbrella study to evaluate the safety, tolerability, and clinical activity of investigational agents for newly diagnosed, high-risk, earlystage…MK-5890 / Keytruda / Abraxane / Carboplatin / Doxorubicin / Epirubicin /… | Merck & Co. (MSD) | Pending |
| Mar 27, 2024 | Optimice-pcr: de-escalation of therapy in early-stage TNBC patients who achieve pcr after neoadjuvant chemotherapy with checkpoint inhibitor therapyKeytruda | Canadian Cancer Trials Group, Cancer Research Institute, Queen's University | Ongoing |
| Jan 17, 2024 | Il-1 inhibition for patients with early stage triple negative and er-low breast cancer: a window-of-opportunity studyAnakinra | Princess Margaret Cancer Centre | Pending |
| Nov 16, 2023 | Efficacy of intralesional IL-2 for resectable triple negative breast cancerProleukin | Dr. Gregory Christopher Knapp, Qe Ii Health Sciences Centre, Nova Scotia Health | Pending |
| Sep 22, 2023 | A phase III, open-label, randomised study of neoadjuvant datopotamab deruxtecan (dato-dxd) plus durvalumab followed by adjuvant durvalumab with or without…Datopotamab deruxtecan (dato DXD/DS-1062A) / Imfinzi / Keytruda | AstraZeneca Pharmaceuticals | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA